Facing Headwinds on New Alzheimer’s Drug, Biogen Launches Controversial Campaign
(By Julie Appleby for Kaiser Health News) Do you sometimes lose your train of thought or feel a bit more
Read More
FDA
Analysis: Necessary or Not, Covid Booster Shots Are Probably on the Horizon
(By Elisabeth Rosenthal for Kaiser Health News) The drugmaker Pfizer recently announced that vaccinated people are likely to need a
Read MoreDying Patients With Rare Diseases Struggle to Get Experimental Therapies
(By Christina Bennett for Kaiser Health News) At 15, Autumn Fuernisen is dying. She was diagnosed at age 11 with
Read MoreWhy We May Never Know Whether the $56,000-a-Year Alzheimer’s Drug Actually Works
(By Elisabeth Rosenthal for Kaiser Health News) The Food and Drug Administration’s approval in June of a drug purporting to
Read MoreThe Ensuring Patient Access to Critical Breakthrough Products Act
The bipartisan bill, The Ensuring Patient Access to Critical Breakthrough Products Act, would require Medicare to cover all breakthrough devices
Read MoreQ&A: The CEO of the Alzheimer’s Association on the approval of Aduhelm — and why critics should stop dwelling on the decision
(By Andrew Joseph for STAT) Harry Johns is ready to stop talking about whether or not the Food and Drug
Read More‘I’m just winging it’: Faced with confusing data on the new Alzheimer’s drug, doctors scramble to advise their patients
(By Elizabeth Cooney for STAT) Their phones are ringing off the hook and their email inboxes are filling up with
Read MoreNew Device Taps Brain Signals To Help Stroke Patients Regain Hand Function
(By Jon Hamilton for NPR) People recovering from a stroke will soon have access to a device that can help
Read MoreFDA Weighs Approval of a Lucrative Alzheimer’s Drug but Benefits Are Iffy
(By Harris Meyer for Kaiser Health News) The Food and Drug Administration’s decision next week whether to approve the first
Read MoreBiden Administration Signals It’s in No Rush to Allow Canadian Drug Imports
(By Phil Galewitz for Kaiser Health News) The Biden administration said Friday it has no timeline on whether it will
Read More